Genzyme, Isis Start Pivotal Trial for High Cholesterol

Xconomy Boston — 

Cambridge, MA-based Genzyme (NASDAQ: GENZ) and its partner, Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS), said today they have started a pivotal clinical trial for patients with a genetic disorder that causes exceptionally high levels of cholesterol. The study will enroll 100 patients in the U.S. and Canada, to take 200 milligrams of the experimental drug mipomersen or a placebo each week for about six months. Data from the trial, the first of four new studies the companies plan to initiate by year’s end, will be available in 2010.